MARKET

SELB

SELB

Selecta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.540
-0.060
-2.31%
After Hours: 2.540 0 0.00% 16:00 09/21 EDT
OPEN
2.590
PREV CLOSE
2.600
HIGH
2.595
LOW
2.460
VOLUME
955.48K
TURNOVER
--
52 WEEK HIGH
4.830
52 WEEK LOW
1.280
MARKET CAP
272.14M
P/E (TTM)
-2.5438
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Selecta Biosciences enters into $35M financing facility
Selecta Biosciences (SELB -3.1%) has secured $35M debt financing with Oxford Finance and Silicon Valley Bank, available in two tranches including $10M upon
Seeking Alpha - Article · 09/01 14:49
Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank
GlobeNewswire · 09/01 13:00
Selecta Biosciences Secures Up To $35M Debt Financing With Oxford Finance LLC And Silicon Valley Bank
WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc.(NASDAQ:SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune
Benzinga · 09/01 12:09
If You Had Bought Selecta Biosciences' (NASDAQ:SELB) Shares Three Years Ago You Would Be Down 86%
Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So...
Simply Wall St. · 08/28 20:38
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings: Kura Oncology (NASDAQ:KURA): $300M. Alphatec Holdings (NASDAQ:ATEC): $200M. Dynava
seekingalpha · 08/07 16:33
Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Lags Revenue Estimates
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -153.13% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 14:45
Selecta Biosciences (SELB) Q2 Earnings & Sales Miss Estimates
Selecta Biosciences (SELB) miss estimates for earnings and revenues in the second quarter of 2020.
Zacks · 08/06 14:36
Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
* Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royalties * Entered into research license and option agreement with Sarepta for the use o
GlobeNewswire · 08/06 11:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SELB stock price target is 8.43 with a high estimate of 13.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 115
Institutional Holdings: 63.80M
% Owned: 59.54%
Shares Outstanding: 107.14M
TypeInstitutionsShares
Increased
24
15.24M
New
58
-90.72K
Decreased
11
10.31M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Independent Director
Carrie Cox
President/Chief Executive Officer/Director
Carsten Brunn
Chief Financial Officer/Chief Accounting Officer
Bradford Dahms
Chief Operating Officer/Senior Vice President
Lloyd Johnston
Chief Scientific Officer
Takashi Kishimoto
Independent Director
Goran Ando
Independent Director
Timothy Barabe
Independent Director
Scott Myers
Independent Director
Aymeric Sallin
Independent Director
Timothy Springer
Independent Director
Patrick Zenner
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average SELB stock price target is 8.43 with a high estimate of 13.00 and a low estimate of 4.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SELB
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Selecta Biosciences Inc stock information, including NASDAQ:SELB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SELB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SELB stock methods without spending real money on the virtual paper trading platform.